35 /100
MEDIUM RISK
Score updated May 30, 2026

OVID — Ovid Therapeutics Inc. Dilution Risk Tracker

Track OVID dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track OVID — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
0
📊 Float Risk
2
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
34%
📉 Score Deterioration 40%
• Score rose 17 points recently (worsening)
💰 Capital Raise 38%
• Active shelf registration ($60M, 12% of market cap)
• Active ATM program with $60M remaining capacity
🔄 Reverse Split 15%
• 52-week low $0.27 has breached $1
🔔 Track OVID — Get forecast alerts →

💹 Market Data

Market Cap$509.53M
Shares Outstanding186.64M
Float161.29M
Cash$155.52M
Debt$13.07M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 81.7% shares (2025Q4 vs prior)
86 institutional holders · 66.72M shares
#1 RA CAPITAL MANAGEMENT, L.P. 10.71M shares
#2 ADAR1 Capital Management, LLC 8.57M shares
#3 Affinity Asset Advisors, LLC 7.15M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest10.09M
Days to Cover4.6
% of Float6.3%
FINRA data as of May 15, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Mar 31, 2026
xbrl XBRL CONVERTIBLE Dec 31, 2021
424B3 ATM Apr 27, 2026
EFFECT EFFECT Apr 24, 2026
S-3 SHELF Apr 21, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track OVID Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking OVID — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for OVID
📊 OVID FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 OVID Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.